{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Anemias&page=5", "query": { "condition": "Congenital Anemias", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1044, "total_pages": 105, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Anemias&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Anemias&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T12:29:08.081Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02042222", "title": "Novel Dose Escalation to Predict Treatment With Hydroxyurea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Hydroxyurea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "16 Years", "sex": "ALL", "summary": "1 Year to 16 Years" }, "enrollment_count": 70, "start_date": "2013-10", "completion_date": "2020-07-31", "has_results": false, "last_update_posted_date": "2020-11-18", "last_synced_at": "2026-10-11T12:29:08.081Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02042222" }, { "nct_id": "NCT00480506", "title": "Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Thalassemia Major" ], "interventions": [], "intervention_types": [], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-04", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2012-02-23", "last_synced_at": "2026-10-11T12:29:08.081Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00480506" }, { "nct_id": "NCT04784052", "title": "Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fanconi Anemia" ], "interventions": [ { "name": "JSP191", "type": "DRUG" }, { "name": "CliniMACS Prodigy System", "type": "DEVICE" }, { "name": "Depleted Stem Cell Transplant", "type": "BIOLOGICAL" }, { "name": "Rabbit Anti-Thymoglobulin (rATG)", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE", "BIOLOGICAL" ], "sponsor": "Porteus, Matthew, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 18, "start_date": "2021-12-07", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-10-11T12:29:08.081Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04784052" }, { "nct_id": "NCT00004143", "title": "Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Anemia", "Severe Aplastic Anemia", "Paroxysmal Nocturnal Hemoglobinuria (PNH)", "Pure Red Cell Aplasia" ], "interventions": [ { "name": "Campath, Chemo and/or TBI Allo SCT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Rizzieri, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "1999-09", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2014-12-05", "last_synced_at": "2026-10-11T12:29:08.081Z", "location_count": 2, "location_summary": "Orlando, Florida • Durham, North Carolina", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004143" }, { "nct_id": "NCT00578344", "title": "Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sickle Cell Disease", "Hemoglobin SC" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Campath 1H", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide and MESNA", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Tami D. John", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "40 Years", "sex": "ALL", "summary": "Up to 40 Years" }, "enrollment_count": 8, "start_date": "2005-07", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2020-07-31", "last_synced_at": "2026-10-11T12:29:08.081Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00578344" }, { "nct_id": "NCT02990598", "title": "Hydoxyurea Exposure in Lactation A Pharmacokinetics Study (HELPS)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sickle Cell Anemia" ], "interventions": [], "intervention_types": [], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 16, "start_date": "2017-03-20", "completion_date": "2018-06-19", "has_results": false, "last_update_posted_date": "2019-08-26", "last_synced_at": "2026-10-11T12:29:08.081Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02990598" }, { "nct_id": "NCT01586455", "title": "Human Placental-Derived Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mucopolysaccharidosis I", "Mucopolysaccharidosis VI", "Adrenoleukodystrophy", "Niemann-Pick Disease", "Metachromatic Leukodystrophy", "Wolman Disease", "Krabbe's Disease", "Gaucher's Disease", "Fucosidosis", "Batten Disease", "Severe Aplastic Anemia", "Diamond-Blackfan Anemia", "Amegakaryocytic Thrombocytopenia", "Myelodysplastic Syndrome", "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia" ], "interventions": [ { "name": "Human Placental Derived Stem Cell", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "0 Years to 55 Years" }, "enrollment_count": 43, "start_date": "2013-04", "completion_date": "2022-09", "has_results": false, "last_update_posted_date": "2022-10-25", "last_synced_at": "2026-10-11T12:29:08.081Z", "location_count": 3, "location_summary": "Denver, Colorado • Valhalla, New York • Salt Lake City, Utah", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Valhalla", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01586455" }, { "nct_id": "NCT00098826", "title": "SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Undifferentiated Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Acute Promyelocytic Leukemia (M3)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Blastic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "ispinesib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-11", "last_synced_at": "2026-10-11T12:29:08.081Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098826" }, { "nct_id": "NCT06260891", "title": "Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "25 mg/day zinc", "type": "DRUG" }, { "name": "40 mg/day zinc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 34, "start_date": "2026-02-14", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-11T12:29:08.081Z", "location_count": 6, "location_summary": "Oakland, California • Durham, North Carolina • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06260891" }, { "nct_id": "NCT02578017", "title": "ElectroNic Hydroxyurea AdhereNCE: A Strategy to Improve Hydroxyurea Adherence in Patients With Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Mobile DOT", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "19 Years", "sex": "ALL", "summary": "Up to 19 Years" }, "enrollment_count": 71, "start_date": "2014-07", "completion_date": "2019-06", "has_results": false, "last_update_posted_date": "2019-07-10", "last_synced_at": "2026-10-11T12:29:08.081Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02578017" } ] }